You are here

  • Home
  • Archive
  • Volume 6, Issue 1
  • Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment

Article info

Article menu

Download PDFPDF

Research Article
Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment

Authors

  • Yasuko Tada Division of Cancer Immunology, Research Institute / Exploratory Oncology Research and Clinical Trial Center (EPOC)National Cancer Center 6-5-1 Kashiwanoha 277-8577 Kashiwa Chiba Japan Department of Clinical Research in Tumor ImmunologyOsaka University Graduate School of Medicine Osaka Japan PubMed articlesGoogle scholar articles
  • Yosuke Togashi Division of Cancer Immunology, Research Institute / Exploratory Oncology Research and Clinical Trial Center (EPOC)National Cancer Center 6-5-1 Kashiwanoha 277-8577 Kashiwa Chiba Japan PubMed articlesGoogle scholar articles
  • Daisuke Kotani Department of Gastroenterology and Gastrointestinal OncologyNational Cancer Center Hospital East 6-5-1 Kashiwanoha 277-8577 Kashiwa Chiba Japan PubMed articlesGoogle scholar articles
  • Takeshi Kuwata Department of Pathology and Clinical LaboratoriesNational Cancer Center Hospital East Chiba Japan PubMed articlesGoogle scholar articles
  • Eichi Sato Department of Pathology, Institute of Medical ScienceTokyo Medical University Tokyo Japan PubMed articlesGoogle scholar articles
  • Akihito Kawazoe Department of Gastroenterology and Gastrointestinal OncologyNational Cancer Center Hospital East 6-5-1 Kashiwanoha 277-8577 Kashiwa Chiba Japan PubMed articlesGoogle scholar articles
  • Toshihiko Doi Department of Gastroenterology and Gastrointestinal OncologyNational Cancer Center Hospital East 6-5-1 Kashiwanoha 277-8577 Kashiwa Chiba Japan PubMed articlesGoogle scholar articles
  • Hisashi Wada Department of Clinical Research in Tumor ImmunologyOsaka University Graduate School of Medicine Osaka Japan PubMed articlesGoogle scholar articles
  • Hiroyoshi Nishikawa Division of Cancer Immunology, Research Institute / Exploratory Oncology Research and Clinical Trial Center (EPOC)National Cancer Center 6-5-1 Kashiwanoha 277-8577 Kashiwa Chiba Japan Department of ImmunologyNagoya University Graduate School of Medicine Nagoya Japan PubMed articlesGoogle scholar articles
  • Kohei Shitara Department of Gastroenterology and Gastrointestinal OncologyNational Cancer Center Hospital East 6-5-1 Kashiwanoha 277-8577 Kashiwa Chiba Japan PubMed articlesGoogle scholar articles
  1. ↵a yatada{at}east.ncc.go.jp
  2. ↵b yotogash{at}east.ncc.go.jp
  3. ↵c dkotani{at}east.ncc.go.jp
  4. ↵d tkuwata{at}east.ncc.go.jp
  5. ↵e sato-e{at}tokyo-med.ac.jp
  6. ↵f akawazoe{at}east.ncc.go.jp
  7. ↵g tdoi{at}east.ncc.go.jp
  8. ↵h hwada{at}gesurg.med.osaka-u.ac.jp
  9. ↵i +81-4-7133-1111 hnishika{at}ncc.go.jp
  10. ↵j +81-4-7133-1111 kshitara{at}east.ncc.go.jp
View Full Text

Citation

Tada Y, Togashi Y, Kotani D, et al
Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment
Journal for ImmunoTherapy of Cancer 2018;6:106. doi: 10.1186/s40425-018-0403-1

Publication history

  • Received April 20, 2018
  • Accepted September 5, 2018
  • First published October 11, 2018.
Online issue publication 
February 10, 2021

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© The Author(s). Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.